Ahmad Shariftabrizi
Overview
Explore the profile of Ahmad Shariftabrizi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azadinejad H, Farhadi Rad M, Shariftabrizi A, Rahmim A, Abdollahi H
Diagnostics (Basel)
. 2025 Feb;
15(3).
PMID: 39941326
Radioimmunotherapy (RIT) is a novel cancer treatment that combines radiotherapy and immunotherapy to precisely target tumor antigens using monoclonal antibodies conjugated with radioactive isotopes. This approach offers personalized, systemic, and...
2.
Gadens Zamboni C, Dundar A, Jain S, Kruzer M, Loeffler B, Graves S, et al.
EJNMMI Rep
. 2024 Nov;
8(1):39.
PMID: 39613925
Background: Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [Lu]Lu-DOTA-TATE PRRT. Methods: NET patients...
3.
Saad Eddin A, McNeely P, Saad Eldine M, Lai L, Shariftabrizi A
Radiol Case Rep
. 2024 Jan;
19(4):1391-1396.
PMID: 38268737
We report a case of multisystem Langerhans cell histiocytosis in a pediatric patient with central nervous system involvement, highlighting F-18(FDG) uptake characteristics of dural sites of disease. We also highlight...
4.
Akay S, Pollard J, Saad Eddin A, Alatoum A, Kandemirli S, Gholamrezanezhad A, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568575
Sinonasal cancers are uncommon malignancies with a generally unfavorable prognosis, often presenting at an advanced stage. Their high rate of recurrence supports close imaging surveillance and the utilization of functional...
5.
Safaei S, Sajed R, Shariftabrizi A, Dorafshan S, Saeednejad Zanjani L, Manshadi M, et al.
Cancer Cell Int
. 2023 Jul;
23(1):143.
PMID: 37468874
Matrix stiffness is a mechanical characteristic of the extracellular matrix (ECM) that increases from the tumor core to the tumor periphery in a gradient pattern in a variety of solid...
6.
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D
Oncologist
. 2023 Jan;
28(3):246-251.
PMID: 36651837
Background: Radium-223 dichloride (Ra-223) is now frequently used to treat prostate cancer that has metastasized to bone, although patient selection continues to be suboptimal for determining who will benefit most...
7.
Aldine A, Balaawi K, Saadeddin A, Shariftabrizi A, Kandemirl S
Nucl Med Mol Imaging
. 2021 Nov;
55(5):261-264.
PMID: 34721720
A 65-year-old male patient with a past medical history of prostate adenocarcinoma presented with biochemical recurrence (prostate-specific antigen level of 5.91 mg/L). F-FACBC PET/CT was acquired to evaluate the disease...
8.
Shariftabrizi A, Pillenahalli Maheshwarappa R, Kahn D, Pollard J
Clin Nucl Med
. 2020 Oct;
46(2):e97-e99.
PMID: 33031240
A 63-year-old man with recent diagnosis of high-risk prostate adenocarcinoma was referred to our Nuclear Medicine Department for 18F-fluciclovine PET/CT to rule out metastasis in the setting of elevated serum...
9.
Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, Madjd Z
Cancer Manag Res
. 2019 Oct;
11:8669-8698.
PMID: 31576171
Nearly half of patients with colorectal cancer (CRC), the third leading cause of cancer deaths worldwide, are diagnosed in the late stages of the disease. Appropriate treatment is not applied...
10.
Saeednejad Zanjani L, Madjd Z, Abolhasani M, Rasti A, Shariftabrizi A, Mehrazma M, et al.
Pathology
. 2018 Nov;
51(1):21-31.
PMID: 30466948
Human telomerase reverse transcriptase (hTERT) is an active component of telomerase and responsible for its catalytic activity, associated with cell proliferation and differentiation. For the first time, the present study...